Publications by authors named "Robert Manges"

Claim this Profile
S
Safety and efficacy of durvalumab with R-CHOP or R-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas S Larsen, Krish Patel, Robert F Manges

Int J Hematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung function of primary cooks using LPG or biomass and the effect of particulate matter on airway epithelial barrier integrity.
Emma M Stapleton, Abhilash Kizhakke Puliyakote, Nervana Metwali, Matthew Jeronimo, Ian M Thornell, Robert B Manges

Environ Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous in-home PM concentrations of smokers with and without a history of respiratory exacerbations in Iowa, during and after an air purifier intervention.
Emma M Stapleton, Jacob E Simmering, Robert B Manges, Octav Chipara, Elizabeth A Stone

J Expo Sci Environ Epidemiol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indoor Particulate Matter From Smoker Homes Induces Bacterial Growth, Biofilm Formation, and Impairs Airway Antimicrobial Activity. A Pilot Study.
Emma M Stapleton, Robert Manges, Gavin Parker, Elizabeth A Stone, Thomas M Peters

Front Public Health· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre

Am J Hematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Jesus Berdeja, Sundar Jagannath, Jeffrey Zonder, Ashraf Badros, Jonathan L Kaufman, Robert Manges

Clin Lymphoma Myeloma Leuk· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Herbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, Johanna C Bendell, J Thaddeus Beck, Robert Manges

J Clin Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Philippe Rougier, Hanno Riess, Robert Manges, Petr Karasek, Yves Humblet

Eur J Cancer· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Peter M Voorhees, Robert F Manges, Pieter Sonneveld, Sundar Jagannath, George Somlo

Br J Haematol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis